These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24291473)

  • 21. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study.
    Chung S; Ceja H; Gawłowicz J; Avakyan G; McShea C; Schiemann J; Lu S
    Epilepsy Res; 2012 Aug; 101(1-2):92-102. PubMed ID: 22516508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children's hospital.
    McTague A; Kneen R; Kumar R; Spinty S; Appleton R
    Seizure; 2012 Sep; 21(7):529-34. PubMed ID: 22722010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asymptomatic elevation of liver enzymes due to levetiracetam: a case report.
    Sethi NK; Sethi PK; Torgovnick J; Arsura E; Cukierwar F
    Drug Metabol Drug Interact; 2013; 28(2):123-4. PubMed ID: 23420283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks.
    Piña-Garza JE; Schiemann-Delgado J; Yang H; Duncan B; Hadac J; Hunter SJ
    Clin Ther; 2010 Oct; 32(11):1935-50. PubMed ID: 21095488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial.
    Coppola G; Franzoni E; Verrotti A; Garone C; Sarajlija J; Operto FF; Pascotto A
    Brain Dev; 2007 Jun; 29(5):281-4. PubMed ID: 17055681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B cell aplasia and hypogammaglobulinemia associated with levetiracetam.
    Ozdemir H; Sumer S; Karabagli H; Akdemir G; Caliskaner AZ; Artac H
    Ann Saudi Med; 2018; 38(1):65-68. PubMed ID: 29313528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate.
    Fountain NB; Conry JA; Rodríguez-Leyva I; Gutierrez-Moctezuma J; Salas E; Coupez R; Stockis A; Lu ZS
    Epilepsy Res; 2007 Apr; 74(1):60-9. PubMed ID: 17270398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.
    Delanty N; Jones J; Tonner F
    Epilepsia; 2012 Jan; 53(1):111-9. PubMed ID: 22050371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam.
    Eue S; Grumbt M; Müller M; Schulze A
    Epilepsy Behav; 2009 Aug; 15(4):467-9. PubMed ID: 19616482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence.
    Cavitt J; Privitera M
    Arch Neurol; 2004 Oct; 61(10):1604-7. PubMed ID: 15477517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hair loss with levetiracetam in five patients with epilepsy.
    Zou X; Hong Z; Zhou D
    Seizure; 2014 Feb; 23(2):158-60. PubMed ID: 24315496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of levetiracetam in refractory status epilepticus.
    Patel NC; Landan IR; Levin J; Szaflarski J; Wilner AN
    Seizure; 2006 Apr; 15(3):137-41. PubMed ID: 16426869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levetiracetam as a possible cause of fulminant liver failure.
    Tan TC; de Boer BW; Mitchell A; Delriviere L; Adams LA; Jeffrey GP; Macquillan G
    Neurology; 2008 Aug; 71(9):685-6. PubMed ID: 18725594
    [No Abstract]   [Full Text] [Related]  

  • 34. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levetiracetam use and pregnancy outcome.
    ten Berg K; Samrén EB; van Oppen AC; Engelsman M; Lindhout D
    Reprod Toxicol; 2005; 20(1):175-8. PubMed ID: 15808801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of success in the use of oral levetiracetam in status epilepticus.
    Rossetti AO; Bromfield EB
    Epilepsy Behav; 2006 May; 8(3):651-4. PubMed ID: 16495155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levetiracetam for the treatment of generalized dystonia.
    Sullivan KL; Hauser RA; Louis ED; Chari G; Zesiewicz TA
    Parkinsonism Relat Disord; 2005 Nov; 11(7):469-71. PubMed ID: 16014339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.
    Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
    Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study.
    Sahaya K; Goyal MK; Sarwal A; Singh NN
    Epilepsia; 2010 Dec; 51(12):2492-5. PubMed ID: 21204814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypersomnia in an epilepsy patient treated with levetiracetam.
    Khatami R; Siegel AM; Bassetti CL
    Epilepsia; 2005 Apr; 46(4):588-9. PubMed ID: 15816957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.